Natco Pharma shares gained 2.5% in morning trade following the announcement of its ₹2,500 crore investment plan in South Africa. The pharma stock opened at ₹966.35 on the National Stock Exchange (NSE) and climbed to an intraday high of ₹989.50. As of 10:30 AM, the shares were trading 2% higher at ₹986.50, outperforming the Nifty 50 index which was up 0.69%. The stock has gained 11% so far in 2026, significantly outperforming the 8% decline in the Nifty 50. In the past one year, Natco Pharma shares have slipped 3% against a 5.6% fall in the benchmark index.
Natco Pharma has approved investments of nearly ₹2,500 crore in South Africa, as announced by the company on Wednesday. The investment includes ₹1,400 crore to be infused in its wholly-owned subsidiary in the country, with the primary objective of entering new geographies. According to the company's regulatory filing, this strategic move represents a significant expansion of the pharmaceutical company's African market presence. The board of directors approved investing up to ₹1,400 crore in Natco Pharma South Africa Proprietary Ltd, marking a substantial commitment to the African pharmaceutical market.
The company will increase its stake in South Africa-based Adcock Ingram Holdings Proprietary Ltd to 49 per cent from 35.75 per cent, with the acquisition valued at ₹1,069 crore at the prevailing exchange rate. As reported by Business Standard, Natco will acquire 19,618,825 shares for ZAR 92.50 (₹5.89) per share, representing a total investment cost of ZAR 1.8 billion (₹1,069 crore) excluding transaction costs. The transaction is expected to be completed before the end of July 2026. The increase in stake has been executed with the objective of expanding geographic footprint in South Africa and the African continent.
According to Business Standard, the increase in stake in Adcock Ingram has been executed with the objective of expanding geographic footprint in South Africa and the African continent. Founded in 1890 in South Africa, Adcock Ingram operates across four segments -- prescription, consumer, OTC and hospitals. The company maintains a diverse portfolio of products ranging from generic and branded formulations to critical-care hospital products, as well as consumer and home-care products. This strategic acquisition positions Natco for enhanced market penetration across multiple pharmaceutical segments in the African continent.
Hitesh Rathi, research analyst at Angel One, provided insights on Natco Pharma's technical outlook following the investment announcement. He noted that the stock has entered a corrective phase, retracing nearly 61.8% of its preceding up move from the lows around the ₹530 mark after a remarkable rally from 2023 lows. The stock continues to hold above its crucial long-term support band in the ₹820–760 zone, with buyers likely to defend the broader structure as long as this support cluster remains intact. However, the overall technical outlook has shifted from bullish to sideways, with the formation of a Bearish 100% Pole on the higher-timeframe 3% × 3 Point & Figure chart warranting caution. A decisive break down below the ₹820–760 support zone would signal deterioration in the technical structure and potentially mark the beginning of a primary downtrend.
